Jonathan S. Cebon - Olivia Newton-John Cancer and Wellness Centre, University of Melbourne

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 448 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Figure S1 from Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules

Georgina V. Long,Caroline Robert, Marcus O. Butler, Felix Couture, Matteo S. Carlino,Steven O'Day, Victoria Atkinson,Jonathan S. Cebon, Michael P. Brown, Stéphane Dalle, Andrew G. Hill,Geoffrey T. Gibney,Steven McCune, Alexander M. Menzies,Cuizhen Niu, Nageatte Ibrahim,Blanca Homet Moreno,Adi Diab

crossref（2024）

Cited0Views0Bibtex

713MO Nivolumab and Ipilimumab Combination Treatment in Advanced Gynaecological Clear Cell Cancers: Results from the Phase II MoST-CIRCUIT Trial

O. Klein,M.S. Carlino,M. Michael,C.R. Underhill, J. So,D. Kee,Y. Antill,W-S. Lam, H. Chan, R.A. Harrup, A. Hamilton, J.B. Palmer,D.M. Thomas, K. Wilkie,J. Cebon,B. Gao

Annals of Oncology（2024）

Cited0Views0Bibtex

998MO Nivolumab and Ipilimumab Combination Treatment in Advanced Dmmr/msi-H Noncolorectal Cancers: Results from the Phase II MoST-CIRCUIT Study

O. Klein,B. Gao, H. Chan,M. Michael,R. Zielinski, J. So, S.J. Harris,D. Kee,I.M. Collins,W-S. Lam, M. Lyle,C.R. Underhill, M. Brown, R.A. Harrup, S.F. Wong, J.B. Palmer, D. Thomas, K. Wilkie,J. Cebon,M.S. Carlino

Annals of Oncology (2024): S679-S680

Cited0Views0Bibtex

282P Nivolumab and Ipilimumab Combination Treatment in Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer

O. Klein,M. Carlino, M. Brown, S. J. Harris,A. Gunjur,C. R. Underhill,R. Zielinski,D. Kee,W-S. Lam, H. Chan, R. A. Harrup, J. So,I. Collins,M. Michael,J. Torres, J. B. Palmer, D. Thomas, K. Wilkie,J. Cebon,A. Nagrial

Annals of Oncology (2024): S119

Cited0Views0Bibtex

Supplementary Figure 3 from Cellular Mechanisms Underlying Complete Hematological Response of Chronic Myeloid Leukemia to BRAF and MEK1/2 Inhibition in a Patient with Concomitant Metastatic Melanoma

Miles C. Andrews,Natalie Turner,Janis Boyd,Andrew W. Roberts,Andrew P. Grigg, Andreas Behren,Jonathan Cebon

openalex（2023）

Cited0Views0Bibtex

Table S1 from Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers

Oliver Klein,Damien Kee,Ben Markman,Michael,Craig Underhill,Matteo S. Carlino,Louise Jackett,Caroline Lum,Clare Scott,Adnan Nagrial,Andreas Behren,Jane Y. So,Jodie Palmer,Jonathan Cebon

openalex（2023）

Cited0Views0Bibtex

Supplementary Figures and Tables from Distinctive Subpopulations of Stromal Cells Are Present in Human Lymph Nodes Infiltrated with Melanoma

Jennifer Eom,Saem Mul Park,Vaughan Feisst,Chun-Jen J. Chen,Joanna E. Mathy,Julie D. McIntosh,Catherine E. Angel,Adam Bartlett,Richard Martin,Jon A. Mathy,Jonathan S. Cebon,Michael A. Black,Anna E.S. Brooks,P. Rod Dunbar

openalex（2023）

Cited0Views0Bibtex

Supplementary Figure 1 from BRAF/NRAS Wild-Type Melanomas Have a High Mutation Load Correlating with Histologic and Molecular Signatures of UV Damage

Victoria J. Mar,Stephen Q. Wong,Jason Li,Richard A. Scolyer,Catriona McLean, Anthony T. Papenfuss,Richard W. Tothill,Hojabr Kakavand, Graham J. Mann,John F. Thompson, Andreas Behren,Jonathan S. Cebon,Rory Wolfe,John W. Kelly,Alexander Dobrovic, Grant A. McArthur

openalex（2023）

Cited0Views0Bibtex

Durable Response to Combination Immunotherapy Using Nivolumab and Ipilimumab in Metastatic Succinate Dehydrogenase (Sdh)-Deficient Gastrointestinal Stroma Tumour

Oliver Klein,Jodie Palmer,Andreas Behren,Jonathan Cebon,Damien Kee

European Journal of Cancer (2023): 113351

Cited0Views0WOSBibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn